Printed From BioPortfolio.com

Novartis breast cancer therapy gets FDA breakthrough designation

01:56 EST 3 Jan 2018 | Reuters

ZURICH (Reuters) - Novartis's Kisqali (ribociclib) has won U.S. Food and Drug Administration breakthrough therapy designation for treating some breast cancer patients, the Swiss drugmaker said on Wednesday.

Original Article: Novartis breast cancer therapy gets FDA breakthrough designation

More From BioPortfolio on "Novartis breast cancer therapy gets FDA breakthrough designation"

Quick Links
Advanced Search | Login | Subscribe | RSS

Quick Search

Relevant Topics

Novartis
Novartis is the fourth largest pharmaceutical company in the world, based on annual sales, which are exceeded $36,000m in 2009. Founded in 1996, Novartis focuses of four main areas; pharmaceuticals, vaccines & diagnostics, generic medicines and biosi...

Cancer
Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...

News Quicklinks

Search Biotech, Medical and Healthcare News

Biotech News by Article Type

BioPortfolio Bloggers

Publishing Your News on BioPortfolio

Recent Visitor News Searches